The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: Gamma Glutamyl Transferase GGT, Gamma-Glutamyl Transferase, Gamma-Glutamyl Transpeptidase, Gamma-GT, GGTP, GTP
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
The Nonalcoholic Fatty Liver Disease Base Assessment panel contains 5 tests with 32 biomarkers.
Nonalcoholic Fatty Liver Disease Base Assessment Panel is a specialized diagnostic tool designed to evaluate key biochemical markers associated with liver function, metabolic health, and cardiovascular risk. This panel offers a comprehensive overview of factors that may contribute to the development or progression of NAFLD, a condition characterized by excessive fat accumulation in the liver unrelated to alcohol consumption. By assessing liver enzymes, glucose regulation, lipid levels, and insulin resistance, this panel helps healthcare providers understand the underlying metabolic disturbances contributing to NAFLD and formulate an effective treatment or management plan.
The Nonalcoholic Fatty Liver Disease Base Assessment panel may be ordered for individuals at risk of NAFLD or those with signs or symptoms suggesting liver dysfunction or metabolic syndrome. Risk factors include obesity, type 2 diabetes, insulin resistance, dyslipidemia, and a sedentary lifestyle. This panel is also commonly ordered for individuals with elevated liver enzyme levels or imaging findings consistent with fatty liver. Early identification and monitoring of NAFLD are critical because the condition can progress to more severe stages, such as nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, or even liver cancer. It may also be used to evaluate individuals with a family history of liver disease or metabolic disorders or to monitor the effectiveness of lifestyle interventions or medical treatments aimed at reducing liver fat and improving metabolic health.
The Nonalcoholic Fatty Liver Disease Base Assessment panel evaluates multiple aspects of metabolic and liver health through a combination of biochemical tests. Each test provides essential insights into the metabolic processes and liver function, offering a holistic understanding of the factors contributing to NAFLD.
The comprehensive metabolic panel (CMP) is a foundational test that evaluates liver function, kidney health, and electrolyte balance. It measures liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which can indicate liver inflammation or damage. The panel also assesses albumin and total protein levels, markers of liver function and nutritional status, as well as bilirubin, which may reveal liver dysfunction. The CMP provides a snapshot of overall health, which is critical for identifying early liver abnormalities associated with NAFLD.
The gamma-glutamyl transferase (GGT) test specifically measures GGT levels, an enzyme found in the liver. Elevated GGT levels may indicate liver dysfunction, bile duct problems, or oxidative stress, all of which are commonly seen in NAFLD. This test helps distinguish between liver-related conditions and provides additional context when evaluating abnormal liver enzyme levels detected in the CMP.
The hemoglobin A1c (HgbA1c) test assesses average blood sugar levels over the past two to three months. Since insulin resistance and impaired glucose metabolism are strongly associated with NAFLD, this test provides critical information about a patient's glycemic control. Elevated HgbA1c levels may indicate prediabetes or diabetes, both of which are key contributors to the development and progression of NAFLD.
The lipid panel measures cholesterol and triglyceride levels, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol. Dyslipidemia, characterized by high triglycerides and low HDL, is a common feature of metabolic syndrome and NAFLD. Understanding a patient’s lipid profile helps healthcare providers identify cardiovascular risks and implement strategies to manage dyslipidemia, which can exacerbate liver inflammation and damage.
The Cardio IQ Insulin Resistance Panel with Score evaluates insulin resistance, a core feature of metabolic syndrome and a major driver of NAFLD. This panel measures fasting insulin and glucose levels and calculates an insulin resistance score, providing a detailed assessment of the body’s ability to regulate glucose and insulin. Identifying insulin resistance is crucial for addressing the underlying metabolic dysfunction that contributes to liver fat accumulation and progression of NAFLD.
Healthcare professionals use the results of the Nonalcoholic Fatty Liver Disease Base Assessment panel to diagnose and manage NAFLD effectively. If the results indicate elevated liver enzymes, dyslipidemia, insulin resistance, or poor glycemic control, the provider may confirm a diagnosis of NAFLD and evaluate the risk of progression to more severe liver conditions. Based on the results, healthcare professionals may recommend lifestyle modifications, such as dietary changes, increased physical activity, or weight loss, which are key strategies for managing NAFLD. Medications may also be prescribed to control blood sugar, lower cholesterol, or address insulin resistance if lifestyle changes are insufficient.
The results of the panel are also used to monitor the effectiveness of treatment interventions. For example, improvements in liver enzyme levels, lipid profile, or insulin resistance scores over time may indicate a positive response to therapy or lifestyle changes. Conversely, worsening results may prompt further investigation, imaging studies, or a referral to a specialist, such as a hepatologist, for advanced care. The comprehensive nature of this panel allows healthcare providers to take a proactive approach in managing NAFLD and mitigating associated cardiovascular and metabolic risks.
The Nonalcoholic Fatty Liver Disease Base Assessment panel is an essential tool for diagnosing, monitoring, and managing NAFLD, a condition that poses significant risks to liver health and overall well-being. By providing a detailed evaluation of liver function, metabolic health, and cardiovascular risk, this panel empowers healthcare providers to identify and address the underlying factors contributing to NAFLD. Early detection and intervention can prevent disease progression, improve patient outcomes, and reduce the burden of complications associated with NAFLD and its related metabolic disorders.